Bone Biologics CEO Issues Stockholder Letter Highlighting NB1 Clinical Progress, Product Improvements, Year-End Enrollment Goal, Expanded Shelf Life, Interim Trial Update, And 2026 Financial Outlook

One-Year Outlook

The firm expect to achieve a number of value-creating events in the coming year under our cost-efficient business model, including the following:

• Adding additional hospital sites in Australia and completing enrollment in our pilot study by year-end.
• Expanding our shelf life to 24 months from 18-months in preparation for increasing manufacturing scale for a pivotal study.
• Developing a more robust potency assay to better measure NB1's biological activity.
• Providing an interim update on the trial once all the patients have reached six-month follow up.

On June 30th, we completed a public offering raising gross proceeds of $5 million. We expect our current cash position to fund planned operations into the second quarter of 2026.